Thanks to its versatility and the F Ability, multiplex platforms soon to LCMRM T emerge as competition for network Technologies. Since the sequential SRT1720 lacing peptide has revolutionized liquid chromatography with tandem mass spectrometry, biology, is LC MRM capacity To detect and quantify small amounts target a priori th after the m Possible effects that have determined to proteomics study of human diseases. As we have shown, these methods have particular utility in the decoding of the fa It is the genetic material of cancer cells may dictate response to the drug. As more and more personalized cancer treatment and LC MRM technology becomes more sophisticated, the future may be considered, in which the most important determinants of drug response can be determined in samples from each patient. It is hoped that this new therapeutic Ans PageSever k Nnten afford to be tailored to the individual patient, so that the efficiency is maximized and minimized off-target effects.
Malignant melanoma is a major health problem. The incidence of malignant melanoma has increased fa Ht You are in the last four decades, and melanoma is one of the h Most common forms of cancer. In 2011, more than 75,000 Americans will be diagnosed to die IT.1 with melanoma and more than 9,000, 2 Although Selumetinib rare hrlicher than breast cancer, prostate cancer or heart lon, it found potentially’s. It has. A high tendency to h Matogenen and lymphatic spread to regional and distant sites and insensitive to other systemic treatments The survival rate at 5 years in metastatic melanoma is dismal, ranging from 5% to 10% with a median survival time of less than 8 months treatment3 Until recently, the Behandlungsm Limited possibilities for patients with metastatic melanoma.
The Behandlungsm Possibilities are allowed dacarbazine and interleukin-2. Dacarbazine, an alkylating agent, representing a response rate of 10%, with a median duration of response was 4 8 months4 monotherapy with IL-2, an immune modulator, the same overall response rate of 16%, achieved with �% Of patients took a complete remission of the m is possibly the result of the long-term survival in some patients.5 use of IL-2 by the low response rate and its potential serious toxicity th, the Descr several organs about.Limited treatment in specialized cancer centers. These funds remissions are rare, usually of short duration, and the treatment is palliative, especially because neither agent has to be improved to survive permanently.
Improved treatment of high-risk resected advanced and metastatic disease are urgently needed. Last year there were great advances in e treatment of patients with metastatic melanoma. Two officers showed ipilimumab, vemurafenib and better survival rate in patients with advanced melanoma compared with standard treatments. The clinical benefits of these drugs has been achieved after decades of research into the molecular pathogenesis of malignant melanoma. This research identified the tumor and cellular Re immune system abnormalities signal path f the development and progression of melanoma Promoted. Once thought of as a cancer with a dismal record of the negative phase III trials for the treatment, the melanoma is now a type of tumor for clinical evaluation paradigm shift therapeutic strategies.